Stem cell clinical trial registration vs approval
By the Stem Cell Seoul editorial team · Published
When a stem cell or exosome claim cites an NCT number, the number shows that a sponsor or investigator submitted a study record to ClinicalTrials.gov. It does not show that the intervention is approved, effective, suitable for a particular patient, authorised in Korea or lawfully available from a specific clinic.
What registration establishes
ClinicalTrials.gov is a public registry and results database maintained by the US National Library of Medicine. Study information is supplied and updated by the sponsor or principal investigator. Registration makes a protocol record searchable and gives it a stable NCT identifier after submission and NLM quality-control review.
That is useful. A record can show the study design, intervention, eligibility, outcome measures, sponsor, locations, recruitment status and whether summary results have been posted. It lets a reader compare what was planned with what was later reported. It should be read as a structured disclosure, not as a regulator's endorsement.
FDA consumer information on regenerative medicine therapies states that inclusion in ClinicalTrials.gov does not mean a product is lawfully marketed. That statement distinguishes registration from marketing status; it is not used here as a current exhaustive inventory of approved products.
What NLM quality control does not establish
A 2019 ClinicalTrials.gov procedural presentation describes quality-control review as screening for apparent errors, deficiencies and inconsistencies. It does not verify the scientific validity or relevance of submitted information. Responsibility for the study and the accuracy of its record stays with the sponsor or investigator.
The separation is especially clear in NLM's guidance on ethics review: when a study requires review-board approval, it may still be registered before that approval if the status is Not yet recruiting. The record must be updated after approval and before recruiting begins. Registering a study and obtaining ethics approval are separate steps.
| Signal | What it means | What it does not prove |
|---|---|---|
| NCT number | The study has a public registry identifier | Product approval, efficacy or clinic permission |
| Recruiting | The record says enrollment is open | That every reader is eligible or should enroll |
| Completed | The study ended normally | A positive result or regulatory authorisation |
| Results posted | Summary results are publicly available in the registry | Peer review, clinical importance or approval |
How to check a clinical trial record
- Confirm the identifier. Match the NCT number, study title and intervention.
- Read the study type and phase. An observational record answers a different question from an interventional trial.
- Check the sponsor and responsible party. They supply and maintain the record.
- Compare status dates. First posted, last update and recruitment status describe different events.
- Look for posted results. A registered protocol without results cannot establish the outcome. Check for any quality-control comments as well as the results themselves.
- Find the separate regulator record. Approval or authorisation requires the relevant authority's product, indication and jurisdiction-specific documentation.
Why a US registry record cannot prove Korean approval
ClinicalTrials.gov is not a Korean product-authorisation database. A Korean claim needs the exact Korean record for the exact product, indication and regulatory path. The MFDS website is a starting point for checking regulator information, but its general landing page does not establish the status of a product, clinic or procedure.
If a page cites an NCT number as proof that a clinic may provide a stem-cell or exosome intervention, ask: Which Korean authority issued the relevant document? What document number, product or protocol, indication, institution and current status does it name?
Frequently asked questions
Does an NCT number mean a treatment is approved?
No. An NCT number identifies a study record on ClinicalTrials.gov. It is not FDA approval, MFDS authorisation, proof that the intervention works, or permission for a clinic to provide it.
Does ClinicalTrials.gov verify that a study is scientifically valid?
No. NLM performs a limited quality-control review for apparent errors, deficiencies and inconsistencies. NLM states that its staff do not verify the scientific validity or relevance of submitted information.
Can a study be registered before ethics approval?
In some circumstances, yes. NLM says a study that requires human-subjects review may be registered before that approval if its status is Not yet recruiting. The record must be updated when approval is obtained before recruitment begins.
Does a Completed status mean the treatment was successful?
No. Completed describes study progress: the study ended normally and participants are no longer being examined or treated. It does not state whether the primary outcome was met or whether a regulator authorised the intervention.
Can a US trial registration prove Korean approval?
No. Korean product status and permission to conduct or provide a particular intervention require the relevant Korean documents. A ClinicalTrials.gov record cannot substitute for an MFDS or other applicable Korean authority record.
Primary sources
- National Library of Medicine. What kind of website is ClinicalTrials.gov? Registry ownership, submitted-information model and scope.
- National Library of Medicine. Can a study be entered before human-subjects review-board approval? Registration and ethics-review timing.
- ClinicalTrials.gov glossary. Definitions for registration, recruitment status and results records.
- ClinicalTrials.gov. Posting submitted summary results: quality-control review process. 2019 procedural presentation; apparent-problem screening and posting with comments.
- US Food and Drug Administration. Important patient and consumer information about regenerative medicine therapies. Narrow source for registration versus lawful marketing status.
- 식품의약품안전처 (Ministry of Food and Drug Safety). Korean regulator context; its existence does not establish any particular product or provider status.
Related guides: FDA approval language, Korean regenerative-medicine law and how to compare evidence levels.